InfuSystem Holdings, Inc. (INFU)

From the record

InfuSystem Holdings, Inc.'s filings since 2017 show 5 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2024-04-03); an auditor change (8-K item 4.01, 3 times, the latest 2026-03-19); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-03-14) (its current reports).

From the record

InfuSystem Holdings, Inc.'s 9 filed years say what it did: revenue went from $71 million in fiscal 2017 to $143 million in fiscal 2025, up 9.2% a year; it rose in 7 of 8 years; the deepest fall was 6% from fiscal 2017 to fiscal 2018; net income was positive in 7 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, InfuSystem Holdings, Inc.'s diluted share count shrank about 0.7% a year, and dividends and buybacks returned about 20% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 5 purchases of their own stock on the open market in the year to 2026-10-13, buying about $150 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, InfuSystem Holdings, Inc. earned about 12 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 80 cents per dollar of everything the company owns. Leverage: it owed about 43 cents per dollar of assets, and net share issuance: its share count shrank 2.8% over the year (the filed statements).

From the record

InfuSystem Holdings, Inc.'s standing among 109 graded names in its industry family: revenue of $143 million in fiscal 2025 ranks in the top 42% by size; a net margin of 4.6% ranks in the top 26%; revenue growth of 9.3% a year over the last 3 filed years ranks in the bottom 41% (its annual reports).

From the record

InfuSystem Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lachance, Carrie (President and CEO, as filed), filing under that title since 2025-09-25, 1.1 years (bottom 25% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 3.5 years (bottom 18%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

InfuSystem Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against debt of $20 million leaves -16.3% of its assets as net cash, bottom 20% of its family; cash from operations less capital spending is 16.6% of revenue (top 14%); a gross margin of 56% (bottom 40%) (its annual report).

From the record

InfuSystem Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 9.3% a year over the last three filed years against 9.2% over all 9, speeding up (top 34% of its family); the newest year grew 6.4% (bottom 32%); capital spending grew -17.1% a year (bottom 32%) (its annual reports). InfuSystem Holdings, Inc. reported 2 lines of business in fiscal 2025: Patient Services at $87 million, Device Solutions at $64 million. 2 of 2 grew in the latest filed year, and the largest line is 57% of revenue (its annual report).

From the record

InfuSystem Holdings, Inc.'s newest year against its own record: revenue of $143 million in fiscal 2025 came in 4% below the $149 million its prior three years' pace pointed to (bottom 47% of its family); net income of $7 million against a prior three-year average of $1 million (top 1%); a net margin of 4.6% against 0.8% before (bottom 37%) (its annual reports).